1. AmBisome® Summary of Product Characteristics (UK). Available at: https://www.medicines.org.uk/emc/product/1022/smpc#gref. [Last accessed: March 2023].
2. Pappas PG et al. Nat Rev Dis Primers. 2018;4:18026.
3. Chatelon J et al. Adv Ther. 2019;36(12):3308–3320.
4. Morrell M et al. Antimicrob Agents Chemother. 2005;49(9):3640–3645
5. Pagano L et al. Future Sci OA. 2018;4(6):FSO307
6. Bongomin F et al. J Fungi (Basel). 2017;3(4):57.
7. De Pascale G et al. Curr Opin Crit Care. 2015;21:421–429.
26. Cornely OA et al. Clin Infect Dis. 2007;44(10):1289–1297.
27. Walker L et al. MBio. 2018;9(1):e02383–17.
28. Kosmidis C and Denning DW Thorax 2015;70:270–277.
29. Blot S et al. Curr Opin Crit Care. 2019;25(5):430–437.
30. Almyroudis NG et al. Antimicrob Agents Chemother. 2007;51(7):2587–2590.
31. Meletiadis J et al. Antimicrob Agents Chemother. 2002;46(1):62–68.
References:
1. AmBisome® Summary of Product Characteristics (UK). Available at: https://www.medicines.org.uk/emc/product/1022/smpc#gref. [Last accessed: March 2023].
16. Keady S and Panesar P. EJHP Practice. 2010;16(3):78–80.
17. Stone NR et al. Drugs. 2016;76(4):485–500.
18. Adler-Moore JP et al. Med Mycol. 2016;54(3):223–231.
19. Ullmann A et al. Clin Infect Dis. 2006;43:e29–e38.
20. Wingard JT et al. Clin Infect Dis. 2000;31:1155–1163.
21. Leenders AC et al. Br J Haematol. 1998;103:205–212.
22. Nett JE and Andes DR. Infect Dis Clin North Am. 2016;30:51–83.
23. Chandrasekar P. J Antimicrob Chemother. 2011;66(3):457–465.
24. Lass-Flörl C et al. Antimicrob Agents Chemother. 2008;52(10):3637–3641.
This educational tool is developed and fully funded by Gilead Sciences, and it is intended for healthcare professionals only. It contains information about Gilead products, educational materials on therapy areas, and professional resources.
Prescribing information for Liposomal Amphotericin B